DATA GRAPHICS | Data Byte
Korea’s Alteogen extends run on latest update for its delivery tech
Keytruda approval, EMA recommendation drive a stock already up over 5x since signing Merck delivery deal for berahyaluronidase
September 23, 2025 12:27 AM UTC
Alteogen gained its first major U.S. regulatory win Friday with FDA’s approval of Keytruda Qlex pembrolizumab/berahyaluronidase alfa-pmph. The announcement sent shares of the South Korean company up 7% Monday to KrW507,000.
The subcutaneously delivered version of blockbuster PD-1 mAb Keytruda pembrolizumab uses a novel hyaluronidase Merck & Co. Inc. (NYSE:MRK) licensed from Alteogen Inc. (KOSDAQ:196170) in 2020. EMA’s CHMP also recommended European approval late last week of the new Keytruda...